AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $297.12 billion. The enterprise value is $343.68 billion.
| Market Cap | 297.12B |
| Enterprise Value | 343.68B |
Important Dates
The next confirmed earnings date is Friday, April 26, 2024, before market open.
| Earnings Date | Apr 26, 2024 |
| Ex-Dividend Date | Apr 12, 2024 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has decreased by -0.28% in one year.
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | -0.28% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 71.94% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 61.69 and the forward PE ratio is 14.72. AbbVie's PEG ratio is 0.45.
| PE Ratio | 61.69 |
| Forward PE | 14.72 |
| PS Ratio | 5.47 |
| Forward PS | 5.35 |
| PB Ratio | 28.68 |
| P/FCF Ratio | 13.47 |
| PEG Ratio | 0.45 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.68, with an EV/FCF ratio of 15.58.
| EV / Earnings | 70.67 |
| EV / Sales | 6.33 |
| EV / EBITDA | 20.68 |
| EV / EBIT | 43.37 |
| EV / FCF | 15.58 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 5.73.
| Current Ratio | 0.87 |
| Quick Ratio | 0.63 |
| Debt / Equity | 5.73 |
| Debt / EBITDA | 3.57 |
| Debt / FCF | 2.69 |
| Interest Coverage | 4.71 |
Financial Efficiency
Return on equity (ROE) is 40.00% and return on invested capital (ROIC) is 14.25%.
| Return on Equity (ROE) | 40.00% |
| Return on Assets (ROA) | 3.60% |
| Return on Capital (ROIC) | 14.25% |
| Revenue Per Employee | $1.09M |
| Profits Per Employee | $97,260 |
| Employee Count | 50,000 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 5.32 |
Taxes
In the past 12 months, AbbVie has paid $1.38 billion in taxes.
| Income Tax | 1.38B |
| Effective Tax Rate | 22.07% |
Stock Price Statistics
The stock price has increased by +2.27% in the last 52 weeks. The beta is 0.56, so AbbVie's price volatility has been lower than the market average.
| Beta (1Y) | 0.56 |
| 52-Week Price Change | +2.27% |
| 50-Day Moving Average | 174.90 |
| 200-Day Moving Average | 156.53 |
| Relative Strength Index (RSI) | 44.01 |
| Average Volume (30 Days) | 5,623,520 |
Short Selling Information
The latest short interest is 13.12 million, so 0.74% of the outstanding shares have been sold short.
| Short Interest | 13.12M |
| Short Previous Month | 14.27M |
| Short % of Shares Out | 0.74% |
| Short % of Float | 0.74% |
| Short Ratio (days to cover) | 2.04 |
Income Statement
In the last 12 months, AbbVie had revenue of $54.32 billion and earned $4.86 billion in profits. Earnings per share was $2.72.
| Revenue | 54.32B |
| Gross Profit | 33.90B |
| Operating Income | 12.76B |
| Pretax Income | 6.24B |
| Net Income | 4.86B |
| EBITDA | 16.62B |
| EBIT | 7.92B |
| Earnings Per Share (EPS) | $2.72 |
Balance Sheet
The company has $12.82 billion in cash and $59.39 billion in debt, giving a net cash position of -$46.57 billion or -$26.30 per share.
| Cash & Cash Equivalents | 12.82B |
| Total Debt | 59.39B |
| Net Cash | -46.57B |
| Net Cash Per Share | -$26.30 |
| Equity / Book Value | 10.36B |
| Book Value Per Share | 5.85 |
| Working Capital | -4.84B |
Cash Flow
In the last 12 months, operating cash flow was $22.84 billion and capital expenditures -$777.00 million, giving a free cash flow of $22.06 billion.
| Operating Cash Flow | 22.84B |
| Capital Expenditures | -777.00M |
| Free Cash Flow | 22.06B |
| FCF Per Share | $12.48 |
Margins
Gross margin is 62.42%, with operating and profit margins of 23.49% and 8.95%.
| Gross Margin | 62.42% |
| Operating Margin | 23.49% |
| Pretax Margin | 11.49% |
| Profit Margin | 8.95% |
| EBITDA Margin | 30.60% |
| EBIT Margin | 14.59% |
| FCF Margin | 40.62% |
Dividends & Yields
This stock pays an annual dividend of $6.20, which amounts to a dividend yield of 3.70%.
| Dividend Per Share | $6.20 |
| Dividend Yield | 3.70% |
| Dividend Growth (YoY) | 4.84% |
| Years of Dividend Growth | 52 |
| Payout Ratio | 227.94% |
| Buyback Yield | 0.28% |
| Shareholder Yield | 3.98% |
| Earnings Yield | 1.64% |
| FCF Yield | 7.43% |
Analyst Forecast
The average price target for AbbVie is $182.18, which is 8.57% higher than the current price. The consensus rating is "Buy".
| Price Target | $182.18 |
| Price Target Difference | 8.57% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 3.46% |
| EPS Growth Forecast (5Y) | 41.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 1.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 6 |